title: The prognostic value of hematogones in patients with acute myeloid leukemia.
abstract: In acute myeloid leukemia (AML), new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B-lymphocyte precursors that increase in hematological diseases and may influence remission duration in AML. HG detection was prospectively investigated in 262 AML patients to determine its prognostic value. Flow cytometric HG detection was performed in bone marrow aspiration after intensive chemotherapy at the time of hematological recovery. Patients with HGs in bone marrow samples had a significantly better relapse-free survival (RFS) and overall survival (OS) than patients without HGs (P = 0.0021, and P = 0.0016). Detectable HGs independently predicted RFS (HR = 0.61, 95%CI: 0.42 - 0.89, P = 0.012) and OS (HR = 0.59, 95%CI: 0.38 - 0.92, 0.019) controlling for age, ELN classification, the number of chemotherapy cycles to achieve CR, performance status, secondary AML and flow cytometric minimal residual disease (MRD). In intensively treated AML, individual determination of HGs could be useful to stratify the optimal risk-adapted therapeutic strategy after induction chemotherapy. Am. J. Hematol. 91:566-570, 2016. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Hematology, CHU Caen, Cote de Nacre Avenue, 14000, France.
authors.forename: Sylvain P
authors.initials: SP
authors.lastname: Chantepie
authors.affiliation: Department of Biostatistics and Clinical Research, CHU Caen, Cote de Nacre Avenue, 14000, France.|Caen Normandie University, Medical school, Caen, F-14000, France.
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Parienti
authors.affiliation: Hematology Laboratory, CHU Caen, Cote de Nacre Avenue, 14000, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Salaun
authors.affiliation: Department of Hematology, CHU Caen, Cote de Nacre Avenue, 14000, France.
authors.forename: Khaled
authors.initials: K
authors.lastname: Benabed
authors.affiliation: Department of Hematology, CHU Caen, Cote de Nacre Avenue, 14000, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Cheze
authors.affiliation: Department of Hematology, CHU Caen, Cote de Nacre Avenue, 14000, France.
authors.forename: Anne-Claire
authors.initials: AC
authors.lastname: Gac
authors.affiliation: Department of Hematology, CHU Caen, Cote de Nacre Avenue, 14000, France.
authors.forename: Hyacinthe
authors.initials: H
authors.lastname: Johnson-Ansah
authors.affiliation: Department of Hematology, CHU Caen, Cote de Nacre Avenue, 14000, France.
authors.forename: Margaret
authors.initials: M
authors.lastname: Macro
authors.affiliation: Department of Hematology, CHU Caen, Cote de Nacre Avenue, 14000, France.|Caen Normandie University, Medical school, Caen, F-14000, France.
authors.forename: Gandhi
authors.initials: G
authors.lastname: Damaj
authors.affiliation: Department of Hematology, Baclesse Cancer Centre, Caen, General Harris Avenue, 14000, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Vilque
authors.affiliation: Department of Hematology, CHU Caen, Cote de Nacre Avenue, 14000, France.
authors.forename: Oumedaly
authors.initials: O
authors.lastname: Reman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000473:pathology; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D054448:Precursor Cells, B-Lymphoid / Q000166:cytology*; D011379:Prognosis; D012008:Recurrence; D018570:Risk Assessment; D016019:Survival Analysis; D055815:Young Adult